22-HDHA, a derivative of docosahexaenoic acid (DHA), plays a significant role in the modulation of inflammatory responses and resolution pathways in the body. It is particularly noted for its involvement in the biosynthesis of specialized pro-resolving mediators (SPMs), which are crucial for the active resolution of inflammation and the promotion of tissue repair. This compound is studied for its potential therapeutic applications in chronic inflammatory diseases, such as arthritis, cardiovascular diseases, and neurodegenerative disorders. Additionally, 22-HDHA is explored for its protective effects in ocular health, particularly in conditions like dry eye syndrome and age-related macular degeneration. Its role in enhancing the body's natural resolution mechanisms makes it a promising candidate for developing treatments aimed at reducing excessive inflammation without compromising the immune response.